Inductive Bio Job Trends

Inductive Bio logo
1
Active Jobs (Last 14 Days)
0
Fresh Jobs (Last 3 Days)
100%
Jobs with Salary Data

Recent Job Posting Activity (30 Days)

Inductive Bio 30-day hiring trend

Job Category Distribution

Inductive Bio job category distribution
Data spans Mar 20, 2026 through Apr 19, 2026, aggregated by PharmaPayWatch.com. Recent job postings shows the number of jobs posted each day (bars) for the past 30 days with an overlay of the 7 day running average. The rose plot shows how PharmaPayWatch categorizes those jobs to get a better sense of Inductive Bio's recent hiring focus. Note that some jobs aren't categorized by our filters, we exclude those from the rose plot.

Current Inductive Bio Jobs, Salary Data, and Stats

In the last two weeks, Inductive Bio has posted 1 positions. None of those roles offer remote or hybrid work. We've been tracking Inductive Bio since May 21, 2025.

Career Tracks Currently Hiring

Other Software & IT Commercial Scientific Research Data Science

Currently Hiring Office Locations

New York City, San Francisco, or Boston New York City

Current Inductive Bio Jobs

Last updated: Apr 18, 2026

Showing 1 active jobs. Active jobs were posted in the last 14 days. Fresh jobs were posted within the last 3 days. Click a row for more details.

Role

Product Scientist (Computational Chemist)

Comm Apr 7
$180,000 - $220,000
New York City, San Francisco, or Boston
Apply →
Inductive Bio is an AI medicinal chemistry partner. We build virtual labs that help drug discovery teams make better decisions, faster, across the full DMTA cycle. Our platform includes Beacon-1 ADMET prediction models, human dose projection tools, and Indy, an AI medicinal chemistry assistant. Through a partnership with Enamine, we also offer library synthesis and direct-to-dose testing, closing the loop from computational design to experimental validation. Together, these power dozens of small molecule and beyond-rule-of-five programs for biotech and pharma partners. Beacon-1 placed 1st in both the 2025 Polaris and 2026 OpenADMET-ExpansionRx blind competitions, ahead of Merck & Co +...